ABSTRACT
G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.
Subject(s)
Drug Discovery , Pyrazoles/pharmacology , Pyrazoles/pharmacokinetics , Receptors, G-Protein-Coupled/agonists , Administration, Oral , Animals , Biological Availability , Humans , Male , Mice , Models, Molecular , Molecular Conformation , Pyrazoles/administration & dosage , Pyrazoles/chemistry , Pyrrolidines/chemistryABSTRACT
Hyperglucagonemia is implicated in the pathophysiology of hyperglycemia. Antagonism of the glucagon receptor (GCGR) thus represents a potential approach to diabetes treatment. Herein we report the characterization of GRA1, a novel small-molecule GCGR antagonist that blocks glucagon binding to the human GCGR (hGCGR) and antagonizes glucagon-induced intracellular accumulation of cAMP with nanomolar potency. GRA1 inhibited glycogenolysis dose-dependently in primary human hepatocytes and in perfused liver from hGCGR mice, a transgenic line of mouse that expresses the hGCGR instead of the murine GCGR. When administered orally to hGCGR mice and rhesus monkeys, GRA1 blocked hyperglycemic responses to exogenous glucagon. In several murine models of diabetes, acute and chronic dosing with GRA1 significantly reduced blood glucose concentrations and moderately increased plasma glucagon and glucagon-like peptide-1. Combination of GRA1 with a dipeptidyl peptidase-4 inhibitor had an additive antihyperglycemic effect in diabetic mice. Hepatic gene-expression profiling in monkeys treated with GRA1 revealed down-regulation of numerous genes involved in amino acid catabolism, an effect that was paralleled by increased amino acid levels in the circulation. In summary, GRA1 is a potent glucagon receptor antagonist with strong antihyperglycemic efficacy in preclinical models and prominent effects on hepatic gene-expression related to amino acid metabolism.
Subject(s)
Gene Expression Regulation , Hypoglycemic Agents/pharmacology , Pyrazoles/pharmacology , Receptors, Glucagon/antagonists & inhibitors , beta-Alanine/analogs & derivatives , Administration, Oral , Animals , Dose-Response Relationship, Drug , Gene Expression Profiling , Glucagon/blood , Glucagon/chemistry , Glycogen/metabolism , Glycogenolysis , Hepatocytes/drug effects , Hormones/blood , Humans , Iodine Radioisotopes/chemistry , Liver/metabolism , Macaca mulatta , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Chemical , beta-Alanine/pharmacologyABSTRACT
A novel class of 1,3,5-pyrazoles has been discovered as potent human glucagon receptor antagonists. Notably, compound 26 is orally bioavailable in several preclinical species and shows selectivity towards cardiac ion channels, other family B receptors such hGIP and hGLP1, and a large panel of enzymes and additional receptors. When dosed orally, compound 26 is efficacious in suppressing glucagon induced plasma glucose excursion in rhesus monkey and transgenic murine pharmacodynamic models at 1 and 10 mpk, respectively.
Subject(s)
Pyrazoles/chemistry , Receptors, Glucagon/antagonists & inhibitors , Administration, Oral , Animals , Blood Glucose/metabolism , Dogs , Drug Evaluation, Preclinical , Humans , Macaca mulatta , Mice , Mice, Transgenic , Pyrazoles/chemical synthesis , Pyrazoles/pharmacokinetics , Rats , Receptors, Glucagon/metabolism , Structure-Activity RelationshipABSTRACT
A series of conformationally constrained tri-substituted ureas were synthesized, and their potential as glucagon receptor antagonists was evaluated. This effort resulted in the identification of compound 4a, which had a binding IC50 of 4.0 nM and was shown to reduce blood glucose levels at 3 mg/kg in glucagon-challenged mice containing a humanized glucagon receptor. Compound 4a was efficacious in correcting hyperglycemia induced by a high fat diet in transgenic mice at an oral dose as low as 3 mg/kg.
Subject(s)
Receptors, Glucagon/antagonists & inhibitors , Urea/analogs & derivatives , Urea/chemical synthesis , Animals , Blood Glucose/metabolism , CHO Cells , Chromatography, High Pressure Liquid , Cricetinae , Cricetulus , Cyclic AMP/metabolism , Dietary Fats , Drug Design , Gastric Inhibitory Polypeptide/metabolism , Glucagon/antagonists & inhibitors , Half-Life , Humans , Hyperglycemia/chemically induced , Hyperglycemia/prevention & control , Indicators and Reagents , Mice , Mice, Transgenic , Molecular Conformation , Receptors, Glucagon/genetics , Urea/pharmacologyABSTRACT
A novel class of spiro-ureas has been discovered as potent human glucagon receptor antagonists in both binding and functional assays. Preliminary studies have revealed that compound 15 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. Compound 15 is orally bioavailable in several preclinical species and shows selectivity toward cardiac ion channels and other family B receptors, such as hGIP1 and hGLP.
Subject(s)
Receptors, Glucagon/antagonists & inhibitors , Spiro Compounds/pharmacology , Urea/pharmacology , Administration, Oral , Animals , CHO Cells , Cricetinae , Drug Evaluation, Preclinical , Humans , Mice , Mice, Transgenic , Models, Molecular , Spiro Compounds/chemistry , Urea/chemistryABSTRACT
A novel class of antagonists of the human glucagon receptor (hGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice).
